ALZN Alzamend Neuro Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALZN

Price (delayed)

$1.33

Market cap

$6.37M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.63

Enterprise value

$5.66M

?
Relative Growth: Rel. Growth: 20
Relative Strength: Rel. Strength: 22
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 0
Highlights
ALZN's EPS has soared by 77% year-on-year and by 33% since the previous quarter
ALZN's net income has dropped by 94% year-on-year and by 25% since the previous quarter
The quick ratio has shrunk by 91% YoY and by 64% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://alzamend.com/
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of ALZN

ALZN stock price

How has the Alzamend Neuro stock price performed over time
Intraday
5.56%
1 week
9.92%
1 month
-2.92%
1 year
-55.52%
YTD
-26.92%
QTD
10.83%

Financial performance

How have Alzamend Neuro's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$8.77M
Net income
-$8.77M
Gross margin
N/A
Net margin
N/A
ALZN's operating income has dropped by 95% year-on-year and by 25% since the previous quarter
ALZN's net income has dropped by 94% year-on-year and by 25% since the previous quarter

Price vs fundamentals

How does ALZN's price correlate with its fundamentals

Growth

What is Alzamend Neuro's growth rate over time

Valuation

What is Alzamend Neuro stock price valuation
P/E
N/A
P/B
6.9
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ALZN's EPS has soared by 77% year-on-year and by 33% since the previous quarter
The P/B is 116% above the last 4 quarters average of 3.2
ALZN's equity has dropped by 82% year-on-year and by 66% since the previous quarter

Efficiency

How efficient is Alzamend Neuro business performance
ALZN's ROA has plunged by 51% YoY and by 33% from the previous quarter
Alzamend Neuro's ROE has decreased by 46% from the previous quarter and by 35% YoY

Dividends

What is ALZN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALZN.

Financial health

How did Alzamend Neuro financials performed over time
Alzamend Neuro's total assets is 54% more than its total liabilities
The company's total liabilities has surged by 112% YoY but it fell by 28% QoQ
The quick ratio has shrunk by 91% YoY and by 64% QoQ
ALZN's debt is 100% smaller than its equity
ALZN's equity has dropped by 82% year-on-year and by 66% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.